Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial

Stephen J. Nicholls, H. Bryan Brewer, John J P Kastelein, Kathryn A. Krueger, Ming Dauh Wang, Mingyuan Shao, Bo Hu, Ellen McErlean, Steven E. Nissen

Research output: Contribution to journalArticlepeer-review

375 Citations (Scopus)


Context: Interest remains high in cholesteryl ester transfer protein (CETP) inhibitors as cardioprotective agents. Few studies have documented the efficacy and safety of CETP inhibitors in combination with commonly used statins. Objective: To examine the biochemical effects, safety, and tolerability of evacetrapib, as monotherapy and in combination with statins, in patients with dyslipidemia. Design, Setting, and Participants: Randomized controlled trial conducted among 398 patients with elevated low-density lipoprotein cholesterol (LDL-C) or low highdensity lipoprotein cholesterol (HDL-C) levels from April 2010 to January 2011 at community and academic centers in the United States and Europe. Interventions: Following dietary lead-in, patients were randomly assigned to receive placebo (n=38); evacetrapib monotherapy, 30 mg/d (n=40), 100 mg/d (n=39), or 500 mg/d (n=42); or statin therapy (n=239) (simvastatin, 40 mg/d; atorvastatin, 20 mg/d; or rosuvastatin, 10 mg/d) with or without evacetrapib, 100 mg/d, for 12 weeks. Main Outcome: Measures: The co-primary end points were percentage changes from baseline in HDL-C and LDL-C after 12 weeks of treatment. Results: The mean baseline HDL-C level was 55.1 (SD, 15.3) mg/dL and the mean baseline LDL-C level was 144.3 (SD, 26.6) mg/dL. As monotherapy, evacetrapib produced dose-dependent increases in HDL-C of 30.0 to 66.0 mg/dL (53.6% to 128.8%) compared with a decrease with placebo of -0.7 mg/dL (-3.0%; P≲λτ∀.001 for all compared with placebo) and decreases in LDL-C of -20.5 to -51.4 mg/dL (-13.6% to -35.9%) compared with an increase with placebo of 7.2 mg/dL (3.9%; P≲λτ∀.001 for all compared with placebo). In combination with statin therapy, evacetrapib, 100 mg/d, produced increases in HDL-C of 42.1 to 50.5 mg/dL (78.5% to 88.5%; P≲λτ∀.001 for all compared with statin monotherapy) and decreases in LDL-C of -67.1 to -75.8 mg/dL (-11.2% to -13.9%; P≲λτ∀.001 for all compared with statin monotherapy). Compared with evacetrapib monotherapy, the combination of statins and evacetrapib resulted in greater reductions in LDL-C (P≲λτ ∀.001) but no greater increase in HDL-C (P=.39). Although the study was underpowered, no adverse effects were observed. Conclusions: Compared with placebo or statin monotherapy, evacetrapib as monotherapy or in combination with statins increased HDL-C levels and decreased LDL-C levels. The effects on cardiovascular outcomes require further investigation. Trial Registration: clinicaltrials.gov Identifier: NCT01105975

Original languageEnglish
Pages (from-to)2099-2109
Number of pages11
JournalJAMA - Journal of the American Medical Association
Issue number19
Publication statusPublished or Issued - 16 Nov 2011

ASJC Scopus subject areas

  • Medicine(all)

Cite this